Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03225846) enrolled 88 people in total across seven groups. Twenty-two participants received a pooled placebo (a dummy treatment), while the remaining 66 received one of six different doses of an investigational drug called WVE-120102, ranging from 2 mg up to 32 mg. The trial was primarily set up to track the number of participants who experienced unwanted health events (called "adverse events") during the study, including those that were severe or serious. It also measured how the drug moved through the body — for example, how high the drug's level in the blood got, and how quickly that peak level was reached. The reported data shows that in the primary outcomes, most participants across all groups — including those on placebo — experienced at least one adverse event during the trial. For example, 20 out of 22 placebo participants had an adverse event, compared to numbers ranging from 4 to 13 out of each active-dose group. Regarding severe adverse events, the highest-dose group (32 mg) had 9 out of 13 participants affected, compared to 2 out of 22 in the placebo group. Serious adverse events (those involving hospitalisation or other significant consequences) were reported for 9 participants in the 32 mg group, compared to none in the placebo group. Six participants in the 32 mg group also withdrew from the trial due to adverse events, while no withdrawals for this reason were reported in any other group. The reported data for the secondary outcomes shows that as the dose increased, the peak level of WVE-120102 measured in the blood generally rose — from approximately 1.35 ng/mL at the 2 mg dose up to 96.21 ng/mL at the 16 mg dose (figures for the 32 mg dose were not reported in the submitted data). The time taken to reach that peak level generally ranged from roughly 1.2 to 3.3 hours across the different dose groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 32250312) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Huntington's Disease Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been pre-screened and found to have a specific genetic marker (a DNA variation) that is on the same gene as the Huntington's disease (HD) mutation (confirm with trial site)
- You are male or female, aged 25 to 65 years old, and are able to walk
- You have been clinically diagnosed with Huntington's disease based on a specific, standardised rating scale used by doctors (called the UHDRS), with a confirmed diagnosis score
- You are in the early stages of HD (Stage I or Stage II), meaning your ability to carry out daily activities falls within a certain range on the UHDRS scoring system
Who may not be able to join:
- You have had cancer, or received treatment for cancer, within the last 5 years — although having had a treated skin cancer (basal cell or squamous cell) may not necessarily exclude you (confirm with trial site)
- You have taken part in another clinical trial involving an experimental drug or implanted device in the last 3 months, or an experimental gene-silencing type drug (oligonucleotide) in the last 6 months or longer
- You have a serious unstable medical condition, unstable mental health symptoms, a substance abuse problem, or are pregnant
- You are unable to have a brain MRI scan for any reason
- You have a condition affecting your bones, spine, or blood clotting, or any other issue that could make a lumbar puncture (spinal fluid sample) risky or difficult to perform
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, MD, Wave Life Sciences
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Safety: Number of Patients With Treatment-emergent Adverse Events (TEAEs); Safety: Number of Patients Who Experienced Severe TEAEs; Safety: Number of Patients With Serious TEAEs; Safety and Tolerability: Number of Patients Who Withdraw Due to TEAEs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.